Skip to main content
PMC home page
International Journal of Molecular Sciences logoLink to International Journal of Molecular Sciences
. 2021 May 27;22(11):5737. doi: 10.3390/ijms22115737

Donor Heart Preservation with Hydrogen Sulfide: A Systematic Review and Meta-Analysis

Imran A Ertugrul 1, Vincent van Suylen 1, Kevin Damman 2, Marie-Sophie L Y de Koning 2, Harry van Goor 3,*, Michiel E Erasmus 1
Editor: Felix B Engel
PMCID: PMC8198118  PMID: 34072153

Abstract

Preclinical studies have shown that postconditioning with hydrogen sulfide (H2S) exerts cardioprotective effects against myocardial ischemia-reperfusion injury (IRI). The aim of this study was to appraise the current evidence of the cardioprotective effects of H2S against IRI in order to explore the future implementation of H2S in clinical cardiac transplantation. The current literature on H2S postconditioning in the setting of global myocardial ischemia was systematically reviewed and analyzed, performing meta-analyses. A literature search of the electronic databases Medline, Embase and Cinahl identified 1835 studies that were subjected to our pre-defined inclusion criteria. Sixteen studies were considered eligible for inclusion. Postconditioning with H2S showed significant robust effects with regard to limiting infarct size (standardized mean difference (SMD) = −4.12, 95% CI [−5.53–−2.71], p < 0.00001). Furthermore, H2S postconditioning consistently resulted in a significantly lower release of cardiac injury markers, lower levels of oxidative stress and improved cardiac function. Postconditioning with slow-releasing H2S donors offers a valuable opportunity for novel therapies within cardiac preservation for transplantation. Before clinical implication, studies evaluating the long-term effects of H2S treatment and effects of H2S treatment in large animal studies are warranted.

Keywords: hydrogen sulfide, ischemia-reperfusion injury, postconditioning, systematic review, meta-analysis, organ preservation, cardiac transplantation

1. Introduction

Cardiac transplantation is the treatment of choice for patients with end-stage heart failure (HF). The global incidence of end-stage HF is rising, while cardiac transplantation is limited by the severe shortage of donor hearts suitable for transplantation [1]. Donation after brain death (DBD) is the current standard for cardiac transplantation. However, in order to enlarge the donor pool, the use of marginal donors and donation after circulatory death (DCD) has gained interest. One of the prominent challenges in cardiac transplantation is myocardial ischemia-reperfusion injury (IRI) to the graft. IRI is the inevitable result of initial restriction of blood supply to the heart followed by subsequent reperfusion. IRI has not only been associated with microvascular dysfunction, arrhythmias and primary graft dysfunction but also with aggravation of tissue damage that has already occurred by circulatory arrest in marginal donors and DCD hearts [2,3].

Static cold storage (CS) is currently the standard method for minimizing IRI during donor heart preservation. Although CS significantly reduces myocardial metabolism, there is a continued metabolism at a lower level, and ischemic damage occurs over time. Continuation of anaerobic metabolism results in depletion of adenosine triphosphate stores, followed by acidosis, ionic disturbances, production of reactive oxygen species (ROS), oxidative stress and eventually necrosis. Re-establishment of blood flow restores homeostasis and is essential to salvage ischemic tissues. However, reperfusion can paradoxically result in further tissue damage by a quick pH change, activation of inflammatory cascades and cell death programs, calcium (Ca2+) overload and increased ROS production [4,5,6]. A maximum period of 4 to 6 h is currently accepted as a safe ischemic preservation time for DBD hearts. Longer ischemic times have been demonstrated to adversely affect post-transplant survival [7]. CS of DCD hearts is insufficient since these hearts have already sustained extensive ischemic injury due to circulatory arrest [8]. Novel strategies to protect the heart from IRI in order to increase the donor pool have been reported, including pharmacological intervention with hydrogen sulfide (H2S).

H2S is an endogenously produced gasotransmitter generated by cystathionine γ-lyase, cystathionine β-synthase and 3-mercaptopyruvate sulfurtransferase. At high concentrations, gasotransmitters are toxic, but at low concentrations, they function as important signaling molecules [9]. In the cardiovascular system, endogenous H2S plays a prominent role in vasodilatation and blood pressure regulation [10]. Multiple exogenous H2S-releasing compounds (H2S donors) are available and have been extensively researched in diverse pathological processes, including myocardial IRI [11]. An increasing body of evidence indicates that pre- and postconditioning the heart with an exogenous H2S donor exerts cardioprotective effects by limiting inflammation and oxidative stress, and by protecting against mitochondrial damage and apoptosis caused by IRI [12,13,14]. In addition, H2S is known to act as a regulator of energy production under stress conditions, which sustains mitochondrial ATP production under hypoxic conditions [15]. These beneficial effects of H2S, especially in H2S postconditioning, could be of additional value in treatment of myocardial infarction (local ischemia) and in the setting of cardiac transplantation and donor heart preservation (global ischemia).

Although H2S therapy against IRI has been investigated abundantly in animal studies, no published comprehensive review on postconditioning with H2S in the setting of global ischemia is available. The aim of this study was to appraise the current evidence of the cardioprotective effects of H2S postconditioning against IRI by systematically reviewing the literature and performing meta-analyses, in order to explore the future implementation of H2S in clinical cardiac transplantation.

2. Results

2.1. Study Selection Process

The initial electronic search identified 1835 studies. After eliminating duplicates, 1078 studies remained. The remaining studies were screened at the title and/or abstract level to check for relevancy to our study scope. Thirty-two studies were considered relevant and full-text reviewed. Finally, 16 studies were included in the analysis (Figure 1).

Figure 1.

Figure 1

Open in a new tab

PRISMA flowchart of the search and selection process of the articles included in this review.

2.2. Main Characteristics

The characteristics of the included studies are summarized in Table 1. All studies were rodent models of IRI (rat n = 14, mouse n = 2). Sodium hydrosulfide (NaHS) was the most commonly used H2S donor (n = 12). Other used H2S donors were sodium thiosulfate (STS) (n = 3), GYY4137, DATS-MSN and sodium sulfate (Na2S) (all n = 1). The H2S donor was administered in the perfusate of Langendorff perfusion (n = 13) or in cold storage solution (n = 3). In Langendorff models, four studies used a postconditioning protocol whereby NaHS was applied in multiple rounds for 10–15 s (ischemic postconditioning) [16,17,18,19]. Evaluated variables relevant to our study scope are shown in Table 2. The definition of infarct size is the area of necrosis in the myocardial tissue. The method of choice to determine infarct size is by 2,3,5-triphenyltetrazolium (TCC) staining. This method has been shown to reliably identify a necrotic myocardium from a viable myocardium. The viable myocardium is stained red as the water-soluble compound TTC is converted by active mitochondrial dehydrogenases into an insoluble red precipitate. The extent of red staining correlates with the number of viable mitochondria and differentiates viable and nonviable tissue. The extent of the area of necrosis is quantified by computerized planimetry [20]. Data regarding inflammation were excluded for meta-analysis since only one study evaluated inflammation (not included in Table 2) [21]. In four of the included studies, multiple intervention groups had the same control group [17,18,21,22]. These additional intervention groups were excluded for meta-analyses. Exclusion was based on the least relevant H2S donor type, dosage and time of intervention.

Table 1.

Main characteristics of included studies. CS = cold storage; m = male; n/g = not given; Na2S = sodium sulfide; NaHS = sodium hydrosulfide; R = reperfusion; STS = sodium thiosulfate. The main characteristics included: (1) ID, (2) Author, (3) Publication year, (4) Species (gender), (5) Number of animals (experimental/control), (6) Study type, (7) H2S donor, (8) Dosage, (9) Time of intervention (during CS/at time of reperfusion), (10) Route of administration, (11) Warm ischemic time (min), (12) Cold ischemic time (h) and (13) Reperfusion time (min).

1 2 3 4 5 6 7 8 9 10 11 12 13
1 Kannan et al. [23] 2019 Rat (m) 6/6 Ex vivo STS 1 µM R Langendorff 30 0 60
2 Sun et al. [21] (A) 2018 Rat (m) 6/6 Transplant NaHS 25 µM CS CS solution 0 4 60
Sun et al. [21] (B) 2018 Rat (m) 6/6 Transplant GYY4137 5 µg/mL CS CS solution 0 4 60
Sun et al. [21] (C) 2018 Rat (m) 6/6 Transplant DATS-MSN 3 µg/mL CS CS solution 0 4 60
3 Ravindran et al. [24] 2018 Rat (n/g) 6/6 Ex vivo STS 1 µM R Langendorff 30 0 60
4 Ansari et al. (I) [25] 2016 Rat (m) 3/3 Ex vivo NaHS 20 µM R Langendorff 30 0 75
5 Ravindran et al. [26] 2017 Rat (m) 6/6 Ex vivo STS 1 µM R Langendorff 30 0 60
6 Ansari et al. (II) [27] 2016 Rat (m) 6/6 Ex vivo NaHS 20 µM R Langendorff 30 0 60
7 Hu et al. [16] 2016 Rat (m) 6/6 Ex vivo NaHS 10 µM R, 4 × 15 s Langendorff 30 0 60
8 Chen et al. [17] (A) 2016 Rat (m) 8/8 Ex vivo NaHS 10 μM R Langendorff 40 0 60
Chen et al. [17] (B) 2016 Rat (m) 8/8 Ex vivo NaHS 10 μM R, 6 × 10 s Langendorff 40 0 60
9 Zhang et al. [28] 2007 Rat (m) 9/9 Ex vivo NaHS 40 µM R Langendorff 30 0 30
10 Sun et al. [29] 2016 Mouse (m) 8/8 Ex vivo NaHS 100 µM R Langendorff 20 0 90
11 Ji et al. [22] (A) 2008 Rat (m) 8/8 Ex vivo NaHS 10 µM R Langendorff 30 0 90
Ji et al. [22] (B) 2008 Rat (m) 8/8 Ex vivo NaHS 0.1 µM R Langendorff 30 0 90
Ji et al. [22] (C) 2008 Rat (m) 8/8 Ex vivo NaHS 1 µM R Langendorff 30 0 90
Ji et al. [22] (D) 2008 Rat (m) 8/8 Ex vivo NaHS 100 µM R Langendorff 30 0 90
12 Luan et al. [19} 2012 Rat (m) 14/14 Ex vivo NaHS 10 µM R, 4 × 15 s Langendorff 30 0 90
13 Hu et al. [30] 2007 Rat (n/g) 6/6 Ex vivo NaHS 1 µM CS CS solution 0 6 30
14 Alves et al. [31] 2010 Rat (m) 5/5 Ex vivo NaHS 100 µM CS CS solution 0 4 30
15 Li et al. [18] (A) 2015 Rat (m) 8/8 Ex vivo NaHS 10 µM R Langendorff 40 0 60
Li et al. [18] (B) 2015 Rat (m) 8/8 Ex vivo NaHS 10 µM R, 5 × 10 s Langendorff 40 0 60
16 Minamishima et al. [32] 2009 Mouse (m) 8/6 Ex vivo Na2S 10 µM R Langendorff 20 0 60
Open in a new tab

Table 2.

Evaluated variables in included studies. * timing of evaluation: 30 min WIT, 15 min R. AI, apoptosis index; BAX, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2 protein; C3, caspase-3; C9, caspase-9; CAT, catalase; CK, creatine kinase; CI, cardiac injury; dP/dtmax, maximal pressure rise; dP/dtmin, minimal pressure rise; EF, ejection fraction; FR, flow rate; GPx, glutathione peroxidase; GR, glutathione reductase; GSH, glutathione; HR, heart rate; LDH, lactate dehydrogenase; LVDP, left ventricular develop pressure; LVEDP, left ventricular end-diastolic pressure; MDA, malondialdehyde; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; RPP, rate pressure product; SOD, superoxide dismutase; STAT3, signal transducer and activator of transcription 3.

ID Author Infarct
Size		 CI Markers Apoptosis Markers Oxidative Stress Markers Cardiac Function Timing of Evaluation
1 Kannan et al. [23] Yes CK, LDH GSH, SOD, CAT, GPx, GR LVDP, HR, RPP 90 min
(30 min WIT, 60 min R)
2 Sun et al. [21] No CK, cTnI C3, BAX, AI GSH, SOD, CAT, MDA LVDP, dP/dtmax,
EF, arrhythmia		 270 min
(240 min CIT, 30 min R)
3 Ravindran et al. [24] Yes CK, LDH SOD, CAT, GPx, GR, PGC-1α LVDP, HR 90 min
(30 min WIT, 60 min R)
4 Ansari et al. [25] Yes CK, LDH C3 LVDP, LVEDP, RPP 105 min
(30 min WIT, 75 min R)
5 Ravindran et al. [26] Yes CK, LDH GSH, SOD, CAT, GR, GPx, MDA LVDP, LVEDP,
dP/dtmax, RPP		 90 min
(30 min WIT, 60 min R)
6 Ansari et al. [27] Yes CK, LDH C3 GSH, CAT, GR, GPx, MDA LVDP, LVEDP, RPP 90 min
(30 min WIT, 60 min R)
7 Hu et al. [16] Yes CK, LDH SOD, MDA, PGC-1α LVDP, LVEDP,
LVDP, LVEDP,
dP/dtmax, RPP		 90 min
(30 min WIT, 60 min R)
8 Chen et al. [17] Yes CK, LDH Bcl-2, AI SOD, MDA LVDP, LVEDP, LVDP, LVEDP, dP/dtmax 100 min
(40 min WIT, 60 min R)
9 Zhang et al. [28] No LVDP, dP/dtmax, arrhythmia 60 min
(30 min WIT, 30 min R)
10 Sun et al. [29] Yes LVDP, LVEDP,
dP/dtmax and dP/dtmin,HR, RPP, FR		 110 min
(20 min WIT, 90 min R)
11 Ji et al. [22] Yes CK * LVDP, HR 120 min
(30 min WIT, 90 min R)
12 Luan et al. [19] Yes Bcl-2, BAX, STAT3, AI LVDP, LVEDP,
dP/dtmax, HR		 120 min
(30 min WIT, 90 min R)
13 Hu et al. [30] No AI LVDP, dP/dtmax,
dP/dtmin 		390 min
(360 min CIT, 30 min R)
14 Alves et al. [31] No Bcl-2 LVDP, LVEDP, HR 270 min
(240 min CIT, 30 min R)
15 Li et al. [18] Yes CK, LDH C3, C9,
Bcl-2, AI		 SOD, MDA LVDP, LVEDP,
dP/dtmax. dP/dtmin 		100 min
(40 min WIT, 60 min R)
16 Minamishima et al. [32] No LVDP, dP/dtmax,
dP/dtmin, RPP, FR		 80 min
(20 min, WIT 60 min R)
Open in a new tab

2.3. Risk of Bias Assessment

The use of the SYRCLE risk of bias tool to assess the quality of animal studies indicated an unknown risk of bias for most studies in the majority of categories (Figure 2). The individual risk of bias scores can be found in Table S1. The funnel plot and results from Egger’s regression test showed significant publication bias (p < 0.001).

Figure 2.

Figure 2

Open in a new tab

Quality and risk of bias assessment. Poor reporting of quality indicators (A) resulted in an unclear risk of bias for most types of bias (B). Selection bias = random group allocation, similar baseline groups and blinded group allocation. Performance bias = random housing and blinded intervention. Detection bias = random outcome assessment and blinded outcome assessment. Attrition bias = reporting of drop-outs. Reporting bias = selective outcome reporting.

2.4. Meta-Analysis

2.4.1. Infarct Size

Infarct size measurements were performed in 11 studies. Postconditioning the heart using a H2S donor resulted in a significantly smaller infarct size (standardized mean difference (SMD) = −4.12, 95% confidence interval (CI) [−5.53–−2.71], p < 0.00001; Figure 3). This overall effect size was accompanied by a high degree of heterogeneity (I-square (I2) = 79%, p < 0.00001). In sensitivity analysis, the result remained consistent after excluding the studies one by one. In addition, subgroup analysis was performed with H2S donor groups NaHS or STS. In groups treated with STS, the infarct size was smaller when compared to groups treated with NaHS (SMD = −9.48, 95% CI [−14.74–−4.23] versus SMD = −3.05, 95% CI [−4.22–−1.87], p < 0.02; Figure 3).

Figure 3.

Figure 3

Open in a new tab

Forest plot of studies investigating the effect of H2S postconditioning on myocardial infarct size.

2.4.2. Cardiac Injury Markers

Meta-analysis of eight studies that reported on cardiac injury markers indicated that postconditioning with H2S resulted in significantly lower levels of creatine kinase (CK) compared with no treatment (SMD = −3.94, 95% CI [−5.51–−2.37], p < 0.00001; Figure 4A), with statistically significant heterogeneity (I2 = 79%, p < 0.0001). H2S treatment was also associated with significantly lower lactate dehydrogenase (LDH) levels measured in six studies (SMD = −2.22, 95% CI [−3.63–−0.81], p < 0.002; Figure 4B). Likewise, we observed a high degree of heterogeneity (I2 = 80%, p < 0.0002). For both outcomes, sensitivity analyses did not change the results.

Figure 4.

Figure 4

Open in a new tab

Forest plot of studies investigating the effect of H2S postconditioning on cardiac injury markers (A) CK and (B) LDH.

2.4.3. Oxidative Stress

Superoxide dismutase (SOD) was measured in six studies. Meta-analysis of these studies indicated that postconditioning with H2S was associated with significantly higher levels of SOD (SMD = 3.13, 95% CI [1.61–6.65], p = 0.0009; Figure 5A), with statistically significant heterogeneity (I2 = 86%, p < 0.00001). Meta-analysis of seven studies that reported on malondialdehyde (MDA) indicated that postconditioning with H2S was associated with significantly lower MDA levels compared to no treatment (SMD = −2.79, 95% CI [−3.97–−1.60], p < 0.00001; Figure 5B). This overall effect size was accompanied by a high degree of heterogeneity (I2 = 68%, p < 0.004). For both outcomes, sensitivity analyses did not change the results.

Figure 5.

Figure 5

Figure 5

Open in a new tab

Forest plot of studies investigating the effect of H2S postconditioning on oxidative stress markers (A) SOD and (B) MDA.

2.4.4. Systolic Function

Meta-analysis of 15 studies indicated that postconditioning with H2S resulted in a significantly higher left ventricular (LV) developed pressure (LVDP) compared to no treatment (SMD = 2.38, 95% CI [1.46–3.30], p < 0.00001; Figure 6A), with statistically significant heterogeneity (I2 = 81%, p < 0.00001). Postconditioning the heart using a H2S donor resulted in a significantly higher maximum rate of LV pressure change (dP/dtmax) (SMD = 1.41, 95% CI [0.57–2.25]; Figure 6B) compared with the control (p = 0.001, n = 9 comparisons). This overall effect size was accompanied by a high degree of heterogeneity (I2 = 78%, p < 0.0001). For both outcomes, sensitivity analyses did not change the results.

Figure 6.

Figure 6

Open in a new tab

Forest plot of studies investigating the effect of H2S postconditioning on systolic function parameters (A) LVDP and (B) dP/dt max.

2.4.5. Diastolic Function

Postconditioning with a H2S donor resulted in a significantly lower LV end-diastolic pressure (LVEDP) (SMD = −2.59, 95% CI [−3.99–−1.18]; Figure 7A) compared with the control (p < 0.0003, n = 8 comparisons). This overall effect size was accompanied by a high degree of heterogeneity (I2 = 87%, p < 0.00001). In the treated group, H2S treatment also resulted in a significantly higher minimum rate of pressure change (dP/dtmin) (SMD = 1.42, 95% CI [−0.76–2.09], p < 0.0001, n = 8 comparisons, Figure 7B). Likewise, a high degree of heterogeneity was observed (I2 = 63%, p = 0.008). For both outcomes, sensitivity analyses did not change the results.

Figure 7.

Figure 7

Open in a new tab

Forest plot of studies investigating the effect of H2S postconditioning on diastolic function parameters (A) LVEDP and (B) dP/dt min.

2.4.6. Heart Rate

Postconditioning with a H2S donor resulted in a significantly higher heart rate (HR) (SMD = 1.61, 95% CI [−0.03–3.24]; Figure 8) compared with the control (p = 0.05, n = 6 comparisons). This overall effect size was accompanied by a high degree of heterogeneity (I2 = 86%, p < 0.00001). Sensitivity analyses did not change the results.

Figure 8.

Figure 8

Open in a new tab

Forest plot of studies investigating the effect of H2S postconditioning on HR.

2.5. Meta-Regression Analysis

Meta-regression analyses found a significant association between the used H2S donor and CK (p = 0.008), and a trend towards a significant association between H2S donor and infarct size (p = 0.05) and SOD (p = 0.053). In these outcome variables, STS was more favorable than NaHS. Meta-regression analysis also found a significant association between route of administration and MDA (p = 0.04), with Langendorff being more favorable than CS. No significant association was identified for all other outcomes (LDH, SOD, LVDP, dP/dtmin, dP/dtmax, LVEDP and HR). Meta-regression of the postconditioning method (single bolus versus ischemic conditioning) showed no significant association with one of the outcomes as well.

3. Discussion

In the present systematic review and meta-analysis, we examined the existing experimental data on H2S postconditioning against global myocardial IRI in animal studies. We aimed at including all existing studies that used H2S treatment against IRI induced by low or absent coronary flow in the whole heart (global ischemia). Furthermore, we aimed to determine whether findings in this field are consistent, since clinical translation of H2S treatment for optimization of donor heart preservation could be of additional value. In all the 16 studies reviewed and in meta-analyses, we observed that H2S donors protect the heart against IRI. H2S postconditioning resulted in a significantly smaller infarct size, with greater effect in studies using STS as a H2S donor compared with studies using NaHS as a H2S donor. Furthermore, H2S postconditioning consistently resulted in significantly lower release of cardiac injury markers, lower markers of oxidative stress and higher cardiac function. Postconditioning with STS also showed significant advantageous effects in decreasing CK levels compared with NaHS. Nevertheless, the notable heterogeneity across studies must be highlighted. The infarct-limiting effects of H2S were also evaluated in local ischemia in vivo studies. Karwi et al. evaluated the effects of H2S pre- and postconditioning on myocardial infarction across in vivo preclinical studies using a comprehensive systematic review followed by meta-analysis [33]. This study showed significant infarct-sparing effects of H2S, which is in line with our results, emphasizing the infarct-limiting effects of H2S and potential clinical application in local and global myocardial protection against ischemia.

The most commonly used H2S donor in the reviewed papers is NaHS (n = 13), a fast H2S-releasing inorganic sulfide salt [34]. It was shown that NaHS can preserve cardiac function and reduce myocardial tissue damage in postconditioning studies. However, it is important to note that the cardioprotective effects of H2S depend on its physiological concentration. Subnormal tissue concentrations or low release rates of H2S have the most beneficial effect without toxicity [34]. However, at high concentrations or high release rates, H2S can induce toxicity and cell damage [35]. NaHS releases H2S instantaneously in aqueous solution, resulting in a high concentration of H2S within seconds and a short effective residence time in cardiac tissue [36]. To prevent the potential H2S toxicity, controllable and slow-releasing H2S donors have been designed and successfully demonstrated to have cardioprotective effects [21,36]. One of these controllable H2S sources is STS, a metabolite of the H2S detoxification process which can be adversely used to regenerate H2S. Apart from being a source of H2S, STS itself acts as a calcium chelator and antioxidant [23]. As mentioned before, STS treatment showed in this study more advantageous effects related to infarct size and levels of CK compared to NaHS treatment. STS has great potential due to both the H2S-related effects and the complementary effects of STS itself. Furthermore, additional anti-inflammatory and antioxidant effects of STS are related to its reaction with mitochondrial thiosulfate sulfurtransferase and its subsequent ROS scavenging effects [37]. In addition, pH-sensitive H2S donors have been developed including intramolecular cyclization-based donors (JK) and ammonium tetrathiomolybdate (ATTM) [38,39]. Since ischemic injury leads to reduced pH levels and acidosis, acid-promoted H2S release could be of significance in treating IRI. Both JK donors and ATTM have shown efficiency in reducing cellular damage and limiting infarct size in local ischemia models. In conclusion, slow-releasing and controllable H2S donors have more clinical potential than fast-releasing H2S donors.

In addition to paying attention to the H2S donor choice, the route of administration should be chosen carefully. In this study, subgroup analyses showed that H2S administered in Langendorff perfusate was more advantageous than H2S supplementation in CS solution with regard to lowered MDA levels. Further studies are needed to evaluate the effectiveness of H2S postconditioning in static CS versus H2S usage during reperfusion of the heart, for example, during Buckberg reperfusion [40].

The present study has some limitations. The literature search was restricted to the English language. We acknowledge that this restriction may have led to incomplete retrieval of relevant data. In addition, articles by the same research groups were included, assuming good adherence to scientific integrity, as in this way, valuable results were not overlooked. Lastly, we collected data on various markers of IRI without including time points for assessment of these markers. This might make the interpretation of the results difficult since more damage may occur over time, or, on the contrary, a longer treatment time may improve outcomes.

An important limitation we observed in the included studies is that none of the studies were performed in large animals. Although no single animal model perfectly recreates human pathophysiology, large animal models of cardiovascular research are more eligible for clinical translation than small animal models since determinants of myocardial work, e.g., HR, myocardial energy consumption and anatomy, are more similar between humans and large animals. Furthermore, the differences in the pharmacokinetics, distribution and metabolism of H2S between small and large animals may complicate the step to clinical translation [41]. Therefore, more large animal models for testing the efficacy and safety of H2S treatment against IRI are required before translating H2S therapy for organ preservation to the clinic. Another important aspect we observed in the animal studies is that none of the studies included female animals. Female hearts have an inherent cardioprotective advantage due to a lower inflammatory response in the ischemic myocardium compared to men [42]. Female rat hearts show significantly smaller infarct sizes than male hearts, indicating that there is a sex-specific difference in susceptibility to tissue damage induced by IRI [43]. Female animals or mixed gender studies need to be conducted to explore the sex differences in the susceptibility to IRI and efficiency of H2S treatment against IRI. Furthermore, when looking at study models, all included studies performed beating heart procurements, and none of the studies applied H2S postconditioning in a DCD procedure. Therefore, further studies need to be conducted to explore the possibilities to preserve DCD heart function with H2S, in order to enlarge the donor pool for transplantation with DCD hearts.

Long-term effects of H2S treatment were described in only one of the sixteen papers we reviewed (8-week follow-up time) [21]. Mostly, cardioprotective effects by H2S were investigated after a single dose shortly before ischemia or after reperfusion. As stated previously, transplantation of the treated heart would require long-term evaluation of the cardioprotective effects on the heart. Further (transplantation) studies are needed to determine time-dependent effects of H2S treatment against IRI and evaluate possible beneficial and detrimental effects on all organs, especially in larger animal models since long-term effects of H2S postconditioning against IRI in large animals are not known yet.

4. Materials and Methods

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [44].

4.1. Search Strategy

A systematic electronic literature search was performed using Medline, Cinahl and Embase databases, from inception to 25 August 2020. We used combinations of search terms and keywords including “heart”, “organ transplantation”, “organ preservation”, “hydrogen sulfide” and “reperfusion injury”. Full search terms can be found in Table S2. We performed hand searching of the reference list of selected articles from the electronic searches to ensure inclusion of any studies not found by the primary search.

4.2. Eligibility Criteria

Eligibility criteria were developed in accordance with the PICOS approach [45]. Studies were included if they met the following eligibility criteria: (1) original article examining the effects of postconditioning the heart with H2S to limit IRI; (2) in situ or ex situ study; (3) myocardial ischemia was induced by complete cessation of coronary flow (global ischemia model); (4) one or more of the following outcome variables were included in the study: myocardial infarct size, cardiac injury markers, inflammation, oxidative stress or cardiac function. Studies without a documented ischemia and reperfusion time, type of exogenous H2S donor, H2S donor dosage, timing and route of administration were excluded. Studies were also excluded if the H2S donor was administered in combination with another pharmacological treatment, and studies involving animal models with induced non-coronary/non-myocardial diseases at baseline were also excluded.

4.3. Data Extraction

Data extraction was performed by one reviewer. If inclusion of articles was questionable, a second and a third reviewer reviewed these particular articles. Publications were retrieved from the electronic literature databases and checked for duplication. Initially, the references were reviewed based on the titles and abstracts. Then, relevant articles were fully read and assessed. Study characteristics were divided into first author, publication year, species, gender, number of included animals, study type (in or ex situ), H2S donor, dosage, time of intervention and route of administration of the H2S donor. The primary outcome variable was myocardial infarct size. Secondary outcome variables were divided into cardiac injury markers, inflammation, oxidative stress and functional parameters.

4.4. Risk of Bias Assessment

Risk of bias was assessed using SYRCLE’s RoB tool [46]. This tool, based on the Cochrane Collaboration RoB Tool, aims to assess methodological quality and has been adapted to aspects of bias that play a role in animal experiments, including (1) selection bias, (2) performance bias, (3) detection bias, (4) attrition bias and (5) reporting bias.

4.5. Statistical Analysis

All outcome measures were treated as continuous data. Data were presented as SMD with 95% CI. Every outcome evaluated in at least five studies was analyzed. The random effects model was used for pooling results. The H2S-treated group was compared with the control group (no treatment/placebo) by use of the weighted mean difference (WMD). Heterogeneity was quantified using the I2 statistics test. An I2 higher than 50% was considered indicative of significant heterogeneity. Forest plots were created to summarize the meta-analysis study results. Meta-regression analyses were performed to examine an association between type of H2S donor, postconditioning method (single bolus or ischemic conditioning) and route of administration in all outcome variables. Publication bias was assessed by inspection of funnel plots and quantified by Egger’s test. A p-value < 0.05 was considered statistically significant. Statistical analyses and figures were performed and composed with Review Manager (RevMan 5.3.5 Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and Stata (StataCorp, College, TX, USA).

5. Conclusions

This systematic review provides an overview of the cardioprotective effects of H2S postconditioning against IRI in the setting of global ischemia. The included studies showed robust beneficial effects of H2S postconditioning with regard to infarct size, cardiac injury markers, oxidative stress and cardiac function. Postconditioning with slow-releasing H2S donors might offer a valuable opportunity for novel therapies within cardiac preservation for transplantation. Before clinical implication, studies evaluating the (long-term) effects of H2S treatment in large and female/mixed animal studies are warranted.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ijms22115737/s1.

Click here for additional data file. (314KB, zip)

Author Contributions

I.A.E., investigation, formal analysis and writing; V.v.S., investigation and writing; K.D., formal analysis; M.-S.L.Y.d.K., writing; H.v.G., conceptualization, supervision and writing; M.E.E., conceptualization, supervision and writing. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Virani S.S., Alonso A., Benjamin E.J., Bittencourt M.S., Callaway C.W., Carson A.P., Chamberlain A.M., Chang A.R., Cheng S., Delling F.N., et al. Heart Disease and Stroke Statistics—2020 Update: A Report from the American Heart Association. Circulation. 2020;141:e139–e596. doi: 10.1161/cir.0000000000000757. [DOI] [PubMed] [Google Scholar]
  • 2.Yellon D.M., Hausenloy D.J. Myocardial Reperfusion Injury. New Engl. J. Med. 2007;357:1121–1135. doi: 10.1056/NEJMra071667. [DOI] [PubMed] [Google Scholar]
  • 3.Matsumura K., Jeremy R.W., Schaper J., Becker L.C. Progression of Myocardial Necrosis during Reperfusion of Ischemic Myocardium. Circulation. 1998;97:795–804. doi: 10.1161/01.CIR.97.8.795. [DOI] [PubMed] [Google Scholar]
  • 4.Eltzschig H.K., Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat. Med. 2011;17:1391–1401. doi: 10.1038/nm.2507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Vinten-Johansen J., Jiang R., Reeves J.G., Mykytenko J., Deneve J., Jobe L.J. Inflammation, Proinflammatory Mediators and Myocardial Ischemia–reperfusion Injury. Hematol. Clin. N. Am. 2007;21:123–145. doi: 10.1016/j.hoc.2006.11.010. [DOI] [PubMed] [Google Scholar]
  • 6.Hausenloy D.J., Yellon D.M. Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J. Clin. Investig. 2013;123:92–100. doi: 10.1172/JCI62874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Banner N.R., Thomas H.L., Curnow E., Hussey J.C., Rogers C.A., Bonser R.S. The Importance of Cold and Warm Cardiac Ischemia for Survival after Heart Transplantation. Transplantation. 2008;86:542–547. doi: 10.1097/TP.0b013e31818149b9. [DOI] [PubMed] [Google Scholar]
  • 8.Quader M., Toldo S., Chen Q., Hundley G., Kasirajan V. Heart transplantation from donation after circulatory death donors: Present and future. J. Card. Surg. 2020;35:875–885. doi: 10.1111/jocs.14468. [DOI] [PubMed] [Google Scholar]
  • 9.Kimura H. Production and Physiological Effects of Hydrogen Sulfide. Antioxid. Redox Signal. 2014;20:783–793. doi: 10.1089/ars.2013.5309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zhao W., Zhang J., Lu Y., Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J. 2001;20:6008–6016. doi: 10.1093/emboj/20.21.6008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wu D., Wang J., Li H., Xue M., Ji A., Li Y. Role of Hydrogen Sulfide in Ischemia-Reperfusion Injury. Oxidative Med. Cell. Longev. 2015;2015:1–16. doi: 10.1155/2015/186908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zanardo R.C.O., Brancaleone V., Distrutti E., Fiorucci S., Cirino G., Wallace J.L. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006;20:2118–2120. doi: 10.1096/fj.06-6270fje. [DOI] [PubMed] [Google Scholar]
  • 13.Elrod J., Calvert J., Morrison J., Doeller J.E., Kraus D.W., Tao L., Jiao X., Scalia R., Kiss L., Szabo C., et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc. Natl. Acad. Sci. USA. 2007;104:15560–15565. doi: 10.1073/pnas.0705891104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wu D., Hu Q., Liu X., Pan L., Xiong Q., Zhu Y.Z. Hydrogen sulfide protects against apoptosis under oxidative stress through SIRT1 pathway in H9c2 cardiomyocytes. Nitric Oxide. 2015;46:204–212. doi: 10.1016/j.niox.2014.11.006. [DOI] [PubMed] [Google Scholar]
  • 15.Fu M., Zhang W., Wu L., Yang G., Li H., Wang R. Hydrogen sulfide (H2S) metabolism in mitochondria and its regulatory role in energy production. Proc. Natl. Acad. Sci. USA. 2012;109:2943–2948. doi: 10.1073/pnas.1115634109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hu M.-Z., Zhou B., Mao H.-Y., Sheng Q., Du B., Chen J.-L., Pang Q.-F., Ji Y. Exogenous Hydrogen Sulfide Postconditioning Protects Isolated Rat Hearts From Ischemia/Reperfusion Injury Through Sirt1/PGC-1α Signaling Pathway. Int. Heart J. 2016;57:477–482. doi: 10.1536/ihj.15-506. [DOI] [PubMed] [Google Scholar]
  • 17.Chen J., Gao J., Sun W., Li L., Wang Y., Bai S., Li X., Wang R., Wu L., Li H., et al. Involvement of exogenous H2S in recovery of cardioprotection from ischemic post-conditioning via increase of autophagy in the aged hearts. Int. J. Cardiol. 2016;220:681–692. doi: 10.1016/j.ijcard.2016.06.200. [DOI] [PubMed] [Google Scholar]
  • 18.Li H., Wang Y., Wei C., Bai S., Zhao Y., Li H., Wu B., Wang R., Wu L., Xu C. Mediation of exogenous hydrogen sulfide in recovery of ischemic post-conditioning-induced cardioprotection via down-regulating oxidative stress and up-regulating PI3K/Akt/GSK-3β pathway in isolated aging rat hearts. Cell Biosci. 2015;5:11. doi: 10.1186/s13578-015-0003-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Luan H.-F., Zhao Z.-B., Zhao Q.-H., Zhu P., Xiu M.-Y., Ji Y. Hydrogen sulfide postconditioning protects isolated rat hearts against ischemia and reperfusion injury mediated by the JAK2/STAT3 survival pathway. Braz. J. Med. Biol. Res. 2012;45:898–905. doi: 10.1590/S0100-879X2012007500090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Redfors B., Shao Y., Omerovic E. Myocardial infarct size and area at risk assessment in mice. Exp. Clin. Cardiol. 2012;17:268–272. [PMC free article] [PubMed] [Google Scholar]
  • 21.Sun X., Wang W., Dai J., Huang J., Shi M., Chu X., Wang F., Guo C., Wang C., Pang L., et al. Donor heart preservation with a novel long-term and slow-releasing hydrogen sulfide system. Nitric Oxide. 2018;81:1–10. doi: 10.1016/j.niox.2018.09.001. [DOI] [PubMed] [Google Scholar]
  • 22.Ji Y., Pang Q.-F., Xu G., Wang L., Wang J.-K., Zeng Y.-M. Exogenous hydrogen sulfide postconditioning protects isolated rat hearts against ischemia-reperfusion injury. Eur. J. Pharmacol. 2008;587:1–7. doi: 10.1016/j.ejphar.2008.03.044. [DOI] [PubMed] [Google Scholar]
  • 23.Kannan S., Boovarahan S.R., Rengaraju J., Prem P., Kurian G.A. Attenuation of cardiac ischemia-reperfusion injury by sodium thiosulfate is partially dependent on the effect of cystathione beta synthase in the myocardium. Cell Biophys. 2019;77:261–272. doi: 10.1007/s12013-019-00871-8. [DOI] [PubMed] [Google Scholar]
  • 24.Ravindran S., Kurian G.A. Effect of Sodium Thiosulfate Postconditioning on Ischemia-Reperfusion Injury Induced Mitochondrial Dysfunction in Rat Heart. J. Cardiovasc. Transl. Res. 2018;11:246–258. doi: 10.1007/s12265-018-9808-y. [DOI] [PubMed] [Google Scholar]
  • 25.Ansari S.B., Kurian G.A. Hydrogen sulfide modulates sub-cellular susceptibility to oxidative stress induced by myocardial ischemic reperfusion injury. Chem. Interact. 2016;252:28–35. doi: 10.1016/j.cbi.2016.03.036. [DOI] [PubMed] [Google Scholar]
  • 26.Ravindran S., Hussain S.J., Boovarahan S.R., Kurian G.A. Sodium thiosulfate post-conditioning protects rat hearts against ischemia reperfusion injury via reduction of apoptosis and oxidative stress. Chem. Interact. 2017;274:24–34. doi: 10.1016/j.cbi.2017.07.002. [DOI] [PubMed] [Google Scholar]
  • 27.Banu S.A., Ravindran S., Kurian G.A. Hydrogen sulfide post-conditioning preserves interfibrillar mitochondria of rat heart during ischemia reperfusion injury. Cell Stress Chaperones. 2016;21:571–582. doi: 10.1007/s12192-016-0682-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Zhang Z., Huang H., Liu P., Tang C., Wang J. Hydrogen sulfide contributes to cardioprotection during ischemia–reperfusion injury by opening KATP channels. Can. J. Physiol. Pharmacol. 2007;85:1248–1253. doi: 10.1139/Y07-120. [DOI] [PubMed] [Google Scholar]
  • 29.Sun J., Aponte A.M., Menazza S., Gucek M., Steenbergen C., Murphy E. Additive cardioprotection by pharmacological postconditioning with hydrogen sulfide and nitric oxide donors in mouse heart: S-sulfhydration vs. S-nitrosylation. Cardiovasc. Res. 2016;110:96–106. doi: 10.1093/cvr/cvw037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hu X., Li T., Bi S., Jin Z., Zhou G., Bai C., Li L., Cui Q., Liu W. Possible Role of Hydrogen Sulfide on the Preservation of Donor Rat Hearts. Transplant. Proc. 2007;39:3024–3029. doi: 10.1016/j.transproceed.2007.05.086. [DOI] [PubMed] [Google Scholar]
  • 31.Alves M.G., Soares A.F., Carvalho R.A., Oliveira P.J. Sodium hydrosulfide improves the protective potential of the cardioplegic histidine buffer solution. Eur. J. Pharmacol. 2011;654:60–67. doi: 10.1016/j.ejphar.2010.12.010. [DOI] [PubMed] [Google Scholar]
  • 32.Minamishima S., Bougaki M., Sips P.Y., De Yu J., Minamishima Y.A., Elrod J., Lefer D.J., Bloch K.D., Ichinose F. Hydrogen Sulfide Improves Survival After Cardiac Arrest and Cardiopulmonary Resuscitation via a Nitric Oxide Synthase 3–Dependent Mechanism in Mice. Circulation. 2009;120:888–896. doi: 10.1161/CIRCULATIONAHA.108.833491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Karwi Q.G., Bice J.S., Baxter G.F. Pre- and postconditioning the heart with hydrogen sulfide (H2S) against ischemia/reperfusion injury in vivo: A systematic review and meta-analysis. Basic Res. Cardiol. 2017;113:6. doi: 10.1007/s00395-017-0664-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Caliendo G., Cirino G., Santagada V., Wallace J.L. Synthesis and Biological Effects of Hydrogen Sulfide (H2S): Development of H2S-Releasing Drugs as Pharmaceuticals. J. Med. Chem. 2010;53:6275–6286. doi: 10.1021/jm901638j. [DOI] [PubMed] [Google Scholar]
  • 35.Wang R. Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed. Physiol. Rev. 2012;92:791–896. doi: 10.1152/physrev.00017.2011. [DOI] [PubMed] [Google Scholar]
  • 36.Rose P., Dymock B.W., Moore P.K. GYY4137, a Novel Water-Soluble, H2S-Releasing Molecule. Volume 554. Elsevier; Amsterdam, The Netherlands: 2015. pp. 143–167. [DOI] [PubMed] [Google Scholar]
  • 37.Kruithof P.D., Lunev S., Lozano S.P.A., Batista F.D.A., Al-Dahmani Z.M., Joles J.A., Dolga A.M., Groves M.R., van Goor H. Unraveling the role of thiosulfate sulfurtransferase in metabolic diseases. Biochim. Biophys. Acta BBA Mol. Basis Dis. 2020;1866:165716. doi: 10.1016/j.bbadis.2020.165716. [DOI] [PubMed] [Google Scholar]
  • 38.Kang J., Li Z., Organ C.L., Park C.M., Yang C.T., Pacheco A., Wang D., Lefer D.J., Xian M. PH-Controlled Hydrogen Sulfide Release for Myocardial Ischemia-Reperfusion Injury. J. Am. Chem. Soc. 2016;138:6336–6339. doi: 10.1021/jacs.6b01373. [DOI] [PubMed] [Google Scholar]
  • 39.Dyson A., Dal-Pizzol F., Sabbatini G., Lach A.B., Galfo F., Cardoso J.D.S., Mendonça B.P., Hargreaves I., Pinto B.B., Bromage D.I., et al. Ammonium tetrathiomolybdate following ischemia/reperfusion injury: Chemistry, pharmacology, and impact of a new class of sulfide donor in preclinical injury models. PLoS Med. 2017;14:e1002310. doi: 10.1371/journal.pmed.1002310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Buckberg G.D. Controlled reperfusion after ischemia may be the unifying recovery denominator. J. Thorac. Cardiovasc. Surg. 2010;140:12–18. doi: 10.1016/j.jtcvs.2010.02.014. [DOI] [PubMed] [Google Scholar]
  • 41.Lelovas P.P., Kostomitsopoulos N., Xanthos T.T. A Comparative Anatomic and Physiologic Overview of the Porcine Heart. J. Am. Assoc. Lab. Anim. Sci. 2014;53:432–438. [PMC free article] [PubMed] [Google Scholar]
  • 42.Wang F., Keimig T., He Q., Ding J., Zhang Z., Pourabdollah-Nejad S., Yang X.-P. Augmented healing process in female mice with acute myocardial infarction. Gend. Med. 2007;4:230–247. doi: 10.1016/S1550-8579(07)80043-X. [DOI] [PubMed] [Google Scholar]
  • 43.Johnson M.S., Moore R.L., Brown D.A. Sex differences in myocardial infarct size are abolished by sarcolemmal KATP channel blockade in rat. Am. J. Physiol. Circ. Physiol. 2006;290:H2644–H2647. doi: 10.1152/ajpheart.01291.2005. [DOI] [PubMed] [Google Scholar]
  • 44.Moher D., Liberati A., Tetzlaff J., Altman D.G., The PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6 doi: 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Thomas J., Kneale D., McKenzie J.E., Brennan S.E., Bhaumik S. Determining the Scope of the Review and the Questions It Will Address. Wiley Online Library; Hoboken, NJ, USA: 2019. Cochrane Handbook for Systematic Reviews of Interventions. [Google Scholar]
  • 46.Hooijmans C.R., Rovers M.M., De Vries R.B.M., Leenaars M., Ritskes-Hoitinga M., Langendam M.W. SYRCLE’s risk of bias tool for animal studies. BMC Med. Res. Methodol. 2014;14:43. doi: 10.1186/1471-2288-14-43. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (314KB, zip)

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Articles from International Journal of Molecular Sciences are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES